Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data
Jefferies initiated Candel Therapeutics (NASDAQ:CADL) with a buy rating and $25 price target, citing positive Phase III prostate cancer data. The stock trades at $8.37, with analyst targets ranging from $15 to $29. The company has a strong financial position and plans a 2026 biologics license application. Recent data showed a hazard ratio of 0.70 and 80.4% negative biopsy rate. Other analysts also reiterated buy ratings and raised price targets.
How this was made
The 30-second read
Why it matters
The Phase III results and analyst upgrades could trigger a short‑term rally, but execution risk remains.
Market read
New clinical data and multiple analyst upgrades provide fresh catalyst for CADL, making it a potential short‑term trade idea.
What to watch
Potential competition from other prostate cancer therapies and the need for regulatory approval timelines.
Background
Candel Therapeutics (NASDAQ:CADL) is a clinical‑stage biotech developing immunotherapies for prostate and lung cancer.
Ticker impact
Jefferies initiates coverage on Candel Therapeutics with a buy rating and $25 price target after positive Phase III prostate cancer data.
likely upward pressure as investors price in the favorable Phase III data and higher price targets.
The new Phase III data and multiple analyst upgrades provide fresh, material information that can drive buying interest.
Market effects
Positive biotech trial data may boost sentiment in the oncology biotech sub‑sector.
U.S. biotech stocks could see modest gains as investors rotate into promising clinical candidates.
Limited to investors focused on U.S. listed biotech firms.
Counterpoint
The data are early‑stage and commercial rollout may face reimbursement hurdles, suggesting caution.
Key entities
- AnalystJefferies
Initiated coverage with a buy rating and $25 price target.
- AnalystBofA Securities
Upgraded to Buy and raised price target to $18.
